Výsledky vyhledávání

Supplementary Methods from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Supplementary Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a043a703bb58c6fa6b9de5de2a58e8d7
https://doi.org/10.1158/1078-0432.22480427

Zobrazit plný text záznamu

Supplemental Figure 2B from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Association between pre-treatment CD4+ T-cell density from available baseline tumor tissue (n=14) and the duration of time on treatment in days.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b8b5eba52845695c761885ea1138d92
https://doi.org/10.1158/1078-0432.22480430.v1

Zobrazit plný text záznamu

Trial Protocol from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Trial Protocol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6ae5b9093afbdaca00b04e264deed14
https://doi.org/10.1158/1078-0432.22480424

Zobrazit plný text záznamu

Supplemental Figure 1A from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Waterfall plots demonstrating the percent change in sum of RECIST v1.1 target lesions compared to baseline. Twenty-five out of 26 patients were included; 1 patient withdrew consent and no follow-up imaging was available for review. The waterfall plot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09bfe8780b9746221e86403dfbe8f293
https://doi.org/10.1158/1078-0432.22480442

Zobrazit plný text záznamu

EPCT-02. PBTC-051: FIRST IN PEDIATRICS PHASE 1 STUDY OF CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M IN PEDIATRIC SUBJECTS WITH RECURRENT/REFRACTORY BRAIN TUMORS

Autor: Alberto Broniscer, Tobey J. MacDonald, Ira J. Dunkel, Ovid Trifan, Holly Lindsay, Girish Dhall, Anna Vinitsky, Mehmet Kocak, Jason Fangusaro, Tina Young Poussaint, Arzu Onar-Thomas

Publikováno v: Neuro-Oncology

BACKGROUND CD40 is a co-stimulatory molecule expressed on antigen presenting cells (APCs). APX005M is a CD40 agonist monoclonal antibody which stimulates innate and adaptive anti-tumor immunity through activation of APCs, macrophages, and antigen-spe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::323d621e43237e13172f86bd1aa3e37c
http://europepmc.org/articles/PMC7715375

Zobrazit plný text záznamu

The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities

Autor: Erin L. Filbert, Ovid Trifan, Yongke Zhang, Pia Björck, Xiaodong Yang

Publikováno v: Journal for Immunotherapy of Cancer

Meeting abstracts The co-stimulatory receptor CD40 is a member of the tumor necrosis factor receptor (TNFR) superfamily and plays an important role in the control and regulation of immune activation, especially in crosstalk between T cells and antige

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef62ea07f5d6a94a2aca59d6df0a0eca
http://europepmc.org/articles/PMC4649416

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání